5:18 PM
 | 
Feb 14, 2014
 |  BC Extra  |  Company News

FDA again rejects label expansions for J&J's Xarelto

FDA issued complete response letters for a pair of sNDAs from Johnson & Johnson (NYSE:JNJ) seeking approval of Xarelto rivaroxaban to reduce the risk of thrombotic cardiovascular events and risk of stent thrombosis in combination with antiplatelet therapy in patients with acute coronary syndrome (ACS). J&J could not be reached for details on the contents of the letters. FDA...

Read the full 283 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >